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Abstract
Aims/hypothesis Recent publications of data extracted from
population registries have suggested a possible relationship
between treatment with insulin glargine and increased inci-
dence of cancer/breast cancer. The aim of the present study
was investigate this possible relationship using data from the
manufacturer’s (sanofi-aventis) pharmacovigilance database.
Methods We analysed the manufacturer’s (sanofi-aventis)
pharmacovigilance database for all randomised clinical
trials (RCTs; Phase 2–4) comparing insulin glargine with
any comparator in type 1 or type 2 diabetes. We identified
all serious adverse events coded under the System Organ
Class of ‘neoplasms, benign, malignant and unspecified’.
Treatment-emergent neoplasms judged to be malignant
were included in this analysis.
Results T h ed a t a b a s ei n c l u d e d3 1s t u d i e s ,1 2i nt y p e1
diabetes and 19 in type 2 diabetes. Twenty compared insulin
glargine withNPH insulin, 29 were parallel-group studies and
two had a crossover design. Studies were generally of
6m o n t h s ’ duration, except for trial reference number 4016
(n=1,017), which had a duration of 5 years. Overall, 10,880
people were included in the analysis (insulin glargine, 5,657;
comparator, 5,223). Forty-five people (0.8%) vs 46 people
(0.9%) reported 52 and 48 cases of malignant cancer in the
insulin glargine and comparator groups, respectively (RR
0.90, 95% CI 0.60–1.36). Skin (12 people with 16 events vs
six people with seven events, RR 1.85, 95% CI 0.69–4.92),
colon and rectum (six vs ten people, RR 0.55, 95% CI
0.20–1.52), breast (four vs six people, RR 0.62, 95% CI 0.17–
2.18) and gastrointestinal tract (six vs four people, RR 1.38,
95% CI 0.39–4.90) were the most commonly reported sites.
Conclusions/interpretation In these 31 RCTs, insulin glar-
gine was not associated with an increased incidence of
cancer, including breast cancer, compared with the com-
parator group.
Keywords Cancer.Diabetesmellitus.Insulinanalogues.
Insulin glargine
Abbreviations
ICH International Conference on Harmonisation of
Technical Requirements for Registration of
Pharmaceuticals for Human Use
RCT randomised clinical trial
SEER Surveillance, Epidemiology and End Results
Introduction
Recent publications of data extracts from population
registries have triggered debate about a potential relationship
between treatment with insulin glargine (A21Gly,B31Arg,
B32Arg human insulin) and an increased incidence of cancer
orbreastcancer [1–4]. Here, we fulfil an obligation to report
the evidence from randomised clinical trials (RCTs) within
the manufacturer’s database.
All RCTs sponsored by sanofi-aventis that compared the
use of insulin glargine with another active comparator in
either type 1 or type 2 diabetes and had a treatment duration
of at least 4 weeks were included in this analysis. These
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DOI 10.1007/s00125-009-1530-5studies included people with either type 1 or type 2
diabetes, and were either part of the initial development
plan for the registration of the product (Phase 2 and 3) or
conducted after the commercial launch of insulin glargine
(Phase 4 studies).
Methods
As it is obligatory for all sponsored trials routinely to report
serious adverse events to the manufacturer, and as the
manufacturer has a database of such studies, no literature
search was performed. Only RCTs that compared insulin
glargine with an active comparator and that had a final
clinical study report available for review on 15 May 2009
were included in this analysis.
Studies and ascertainment of malignancy At h o r o u g h
review of the sanofi-aventis safety database for the
identified studies was performed to assess the incidence of
any malignancies that led to reports of serious adverse
events during the conduct of the trials. All RCTs of insulin
glargine were included. All serious adverse events coded in
the Medical Dictionary for Regulatory Activities (Med-
DRA) System Organ Class of neoplasms—benign, malig-
nant and unspecified—were included in the evaluation [5].
An adverse event is classified as serious if it fulfils the
criteria set down by the International Conference on
Harmonisation of Technical Requirements for Registration
of Pharmaceuticals for Human Use (ICH), that is if it: is
life-threatening or results in death; requires inpatient
hospitalisation or prolongation of existing hospitalisation;
results in persistent or significant disability/incapacity; is a
congenital anomaly/birth defect; or is another ‘medically
important’ event that may jeopardise the study participant
or may require intervention to prevent one of the other
outcomes listed in the definition above [6]. The ICH
recommends that cancers are characterised as ‘medically
important’ adverse events and, therefore, are classified as
serious adverse events [6].
All such identified records in the sanofi-aventis pharma-
covigilance database were reviewed, by treatment, by the
manufacturer’s drug safety personnel with experience of
adverse event reporting, and only treatment-emergent neo-
plasms judged to be malignant were included, independent
of treatment group. Each person was counted only once,
although separate counts for people and cases are provided
if more than one malignancy was reported in the same
person. Relative risks and 95% confidence intervals were
calculated for insulin glargine relative to the comparator for
the total incidence of malignancies and for individual
classifications using all identified RCTs in type 1 and type
2 diabetes combined.
Results
The Clintrace sanofi-aventis safety database contains 31
eligible studies. Twelve studies were performed in people
with type 1 diabetes and 19 studies in people with type 2
diabetes; most of the studies compared insulin glargine with
NPH insulin (20 studies). Nearly all (29) were parallel-
group trials (two had a crossover design). Details of these
studies are summarised in Table 1. Most studies were open
label, 19 were of around 6 months in duration, with six of
longer duration, notably the retinopathy study 4016, which
had a duration of 5 years [7].
Overall, 10,880 people were included in the analysis,
with 5,657 people randomised to insulin glargine and 5,223
people randomised to the comparator, representing a total
follow-up time of 4,711 and 4,524 person-years, respec-
tively. Baseline characteristics of the participants were
comparable between treatment groups (Table 2).
Overall, there was no difference in the incidence of
malignancies between insulin glargine-treated people and the
comparatorgroup(Table3), with52casesofmalignantcancer
documented as a serious treatment-emergent event in 45
people in the insulin glargine group (0.8%) and 48 cases in 46
people in the comparator group (0.9%). Among such
malignancies, most occurred in people with type 2 diabetes,
with45casesin39peopleintheinsulinglarginegroup(1.0%)
and 46 cases in 44 people in the comparator group (1.2%).
The corresponding RR for malignant cancer with insulin
glargine compared with the comparator is 0.90 (95% CI
0.60–1.36).
Four cases of malignant breast cancer were reported in
the insulin glargine group (0.1%) and six cases in the
control group (0.1%). The RR for breast cancer is 0.62
(95% CI 0.17–2.18).
These data were primarily driven by the findings in the
5 year RCT (study 4016) that compared insulin glargine
(n=514) with NPH insulin (n=503) in people with type 2
diabetes who were randomised and received treatment [7, 8].
In that study, the overall number of people with neoplasms
was similar in the insulin glargine and NPH insulin groups
(57 [11.1%] and 62 [12.3%] people, respectively) [8]. When
considering only the number of people in the retinopathy
study with malignant neoplasms reported as serious
treatment-emergent events, the rate was also similar in both
groups (insulin glargine vs NPH insulin, 23 cases in 20
people [3.9%] vs 32 cases in 31 people [6.2%]). Finally, the
number of people with breast cancer reported as a serious
adverse event in that study was similar between the two
treatment groups (three [0.6%] vs four [0.8%] cases – there
was also an additional fifth case in the NPH insulin group,
although this was reported as a non-serious adverse event).
Table 4 summarises the sites of all malignancies in the
pooled studies comparing insulin glargine with comparator.
2500 Diabetologia (2009) 52:2499–2506The most frequently reported site (insulin glargine vs
comparator) included the skin (16 events in 12 people
[0.2%] vs seven events in six [0.1%] people, RR 1.85,
95% CI 0.69–4.92), colon and rectum (six [0.1%] vs ten
[0.2%], RR 0.55, 95% CI 0.20–1.52), breast (four [0.1%]
vs six [0.1%], RR 0.62, 95% CI 0.17–2.18) and gastroin-
testinal tract (six [0.1%] vs four [0.1%], RR 1.38; 95% CI
0.39–4.90).
With respect to the type of malignancy, at least two more
tumours were reported in the comparator group vs the
insulin glargine group for the following classifications:
colon and rectum (ten [0.2%] vs six [0.1%]), prostate (three
[0.1%] vs one [0.0%]), neurological (two [0.0%] vs zero
[0.0%]) and bladder (two [0.0%] vs zero [0.0%]). Con-
versely, there were nine more cases of skin cancer in the
insulin glargine group compared with the comparator group
(16 cases in 12 people [0.2%] vs seven cases in six people
[0.1%]), including an imbalance of six (0.1%) to one
(0.0%) for malignant melanoma. However, in the 5 year
Study 4016, the incidence of all melanomas (documented
as serious and non-serious adverse events) was not different
between treatment groups (three each, with one case in the
comparator [NPH insulin] group and two in the insulin
glargine group reported as serious adverse events).
Within the sanofi-aventis safety database, in addition to the
RCTs, there are 26 completed uncontrolled studies with
insulin glargine, involving a total of 68,201 participants with
type 1 or type 2 diabetes treated for up to 3 years. The data
Trial number
(reference)
Comparator Study duration
(weeks)
Participants randomised and treated
(insulin glargine/control arm)
Type 1 diabetes
2002 [15] NPH 4 168/88
2003 [16] NPH 4 223/110
3001 [17] NPH 28 292/293
3003 [18] NPH 28 174/175
3004 [19] NPH 28 264/270
3005 [20] NPH 16 310/309
4003
a Ultralente 6–7 29/27
4005 [21] NPH 32 26/25
4006 [22] NPH 32 53/52
4010 [23] NPH 30 62/63
4030 [24] NPH or lente 24 85/90
4036 [25] Insulin lispro as CSII 24 26/24
Type 2 diabetes
2004 [26] NPH 4 136/68
2006
a ‘Conventional insulin’ 4 57/57
3002 [27] NPH 52 289/281
3006 [28] NPH 28 259/259
3102
a NPH 28 158/159
3502 [29] OGLDs 24 203/197
4001 [30] NPH 28 464/233
4002 [31] NPH 24 367/389
4012 [32] NPH 24 221/223
4013 [33] NPH 28 231/250
4014 [34] Rosiglitazone 24 105/112
4016 [7, 8] NPH 5 years 514/503
4020
a Pioglitazone 48 164/181
4021
a Insulin lispro 25%, insulin
lispro protamine 75%, mix
24 113/99
4022
a OGLDs 48 118/130
4027 [35] NPH 30/70 28 177/187
4040 [36] Insulin lispro 44 205/212
4042 [37] OGLDs and dietary measures 40 103/108
6001 [38] NPH 36 61/49
Table 1 Details of the studies
included in the analysis
aData available from sanofi-
aventis on request
CSII, continuous subcutaneous
insulin infusion (of insulin
lispro [B28Lys,B29Pro human
insulin]); OGLDs, oral
glucose-lowering drugs
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2502 Diabetologia (2009) 52:2499–2506Table 3 All malignant neoplasms reported in controlled clinical trials comparing insulin glargine with a comparator (participants evaluable for safety)
Trial duration Insulin glargine Comparator
No. of patients All malignancies Breast cancer No. of patients All malignancies Breast cancer
No. affected (%)
[no. of events]
No. affected (%)
[no. of events]
No. affected (%)
[no. of events]
No. affected (%)
[no. of events]
Type 1 diabetes (12 trials): insulin glargine vs other basal insulin
3001 292 2 (0.7) [2] 0 293 0 0
3004 264 3 (1.1) [3] 1 (0.4) [1] 270 0 0
3005 310 1 (0.3) [2] 0 309 2 (0.6) [2] 0
2002 168 0 0 88 0 0
2003 223 0 0 110 0 0
3003 174 0 0 175 0 0
4003 29 0 0 27 0 0
4005 26 0 0 25 0 0
4006 53 0 0 52 0 0
4010 62 0 0 63 0 0
4030 85 0 0 90 0 0
4036 26 0 0 24 0 0
Total type 1 1,712 6 (0.4) [7] 1 (0.1) [1] 1,526 2 (0.1) [2] 0
Type 2 diabetes: insulin glargine vs NPH insulin ≤1 year in duration (ten trials)
a
3002 289 3 (1.0) [3] 0 281 7 (2.5) [7] 1 (0.4) [1]
3006 259 6 (2.3) [8] 0 259 3 (1.2) [4] 0
3102 158 1 (0.6) [1] 0 159 1 (0.6) [1] 0
4001 464 3 (0.6) [3] 0 233 1 (0.4) [1] 0
4002 367 0 0 389 1 (0.3) [1] 1 (0.3) [1]
2004 136 0 0 68 0 0
4012 221 0 0 223 0 0
4013 231 0 0 250 0 0
4027 177 0 0 187 0 0
6001 61 0 0 49 0 0
Total 2,363 13 (0.6) [15] 0 2,098 13 (0.6) [14] 2 (0.1) [2]
Type 2 diabetes: insulin glargine vs NPH insulin >1 year in duration (one trial)
4016 514 20 (3.9) [23] 3 (0.6) [3] 503 31 (6.2) [32] 4 (0.8)
b
Type 2 diabetes: insulin glargine vs oral agents (five trials)
3502 203 1 (0.5) [1] 0 197 0 0
4014 105 0 0 112 0 0
4020 164 0 0 181 0 0
4022 118 0 0 130 0 0
4042 103 2 (1.9) [2] 0 108 0 0
Total 693 3 (0.4) [3] 0 728 0 0
Type 2 diabetes: insulin glargine vs other insulin than NPH (three trials)
2006 57 1 (1.8) [1] 0 57 0 0
4021 113 0 0 99 0 0
4040 205 2 (1.0) [3] 0 212 0 0
Total 375 3 (0.8) [4] 0 368 0 0
Total type 2 diabetes 3,945 39 (1.0) [45] 3 (0.1) [3] 3,697 44 (1.2) [46] 6 (0.2) [6]
Grand total 5,657 45 (0.8) [52] 4 (0.1) [4] 5,223 46 (0.9) [48] 6 (0.1) [6]
aOne study used NPH premixed insulin (4027)
bIncludes one recurrent breast cancer; in addition, there was one case of breast cancer present at baseline that was not considered treatment emergent
Diabetologia (2009) 52:2499–2506 2503from these 26 uncontrolled studies represent a total follow-up
time of 22,074 person-years for insulin glargine treatment.
In total, there were 111 cases of malignancy,
including nine cases of breast cancer, reported in these
studies. The overall cancer rate is estimated to be 5.0
cases per 1,000 person-years (111 out of 22,074 person-
years) and the breast cancer rate is estimated to be 82
cases per 100,000 person-years (that is, nine out of
11,027 person-years—the denominator here being the expo-
sure of women in the type 2 diabetes RCTs). In investigator-
sponsoredtrialsandproductregistries(intensifiedmonitoring)
for which no enrolment figures are available, the sanofi-
aventis safety database contains an additional 75 individuals
with malignancies, including nine cases of breast cancer.
Discussion
Based on our analysis of 31 RCTs, insulin glargine was
not associated with an increased incidence of cancer,
including breast cancer, when compared with the control/
comparator group.
The overall incidence of cancer in the trials included in
this analysis was lower in people with type 1 diabetes than
in those with type 2 diabetes, perhaps because the former
were younger and less obese than the people with type 2
diabetes (Table 2), and were exposed for a shorter time.
Obesity increases the risk of colon cancer by as much as
1.5- to 2-fold and accounts for up to 35% of the total
incidence of colon cancer [9]. In terms of age, the
prevalence of cancer increases with increasing age and
peaks in people aged 75 years or older [10, 11]. People with
type 2 diabetes in this analysis were typically in their mid to
late fifties and, thus, the majority were at an age associated
with greater risk for cancer compared with the people with
type 1 diabetes.
The results presented are based on formal RCTs, which
represent level 1—the highest level—of evidence-based
study design. Another advantage of the present analysis is
that the clinical trials database reviewed here included a
large number of people (n=10,880), allowing the opportu-
nity to identify rarer adverse events. Furthermore, the
events were recorded reasonably accurately, as in any
RCT, as the monitoring of adverse events followed the rules
of good clinical practice and international pharmacovigi-
lance regulations [12]. Finally, our analysis included one
long-term 5 year controlled study that showed comparably
reassuring findings, with no differences in the incidence of
Table 4 Location of malignancies in randomised controlled studies of insulin glargine
Classification No. using insulin glargine
(%) [no. of events]
No. in the control group
(%) [no. of events]
Relative risk
(95% CI)
Total number of people 5,657 (100) [52] 5,223 (100) [48] –
Blood 2 (0.04) [2] 1 (0.02) [1] 1.85 ( 0.17–20.36)
Vertebral body 1 (0.02) [1] 0 –
Breast 4 (0.07) [4] 6 (0.11) [6] 0.62 (0.17–2.18)
Nasal 1 (0.02) [1] 0 –
Lung 3 (0.05) [3] 3 (0.06) [3] 0.92 (0.19–4.57)
Gastrointestinal (not otherwise stated) 6 (0.11) [6] 4 (0.08) [4] 1.38 (0.39–4.90)
Colon and rectum 6 (0.11) [6] 10 (0.19) [10] 0.55 (0.20–1.52)
Hepatic and biliary 2 (0.04) [2] 3 (0.06) [3] 0.62 (0.10–3.68)
Pancreas 3 (0.05) [3] 3 (0.06) [3]
a 0.92 (0.19–4.57)
Renal 3 (0.05) [3] 0 –
Prostate 1 (0.02) [1] 3 (0.06) [3] 0.31 (0.03–2.96)
Bladder 0 2 (0.04) [2] –
Genitourinary 3 (0.05) [3] 4 (0.08) [4] 0.69 (0.16–3.09)
Thyroid 2 (0.04) [2] 0 –
Endocrine 0 1 (0.02) [1] –
Neurological 0 2 (0.04) [2] –
Skin 12 (0.21) [16] 6 (0.11) [7] 1.85 (0.69–4.92)
Total number of people with malignancies
b 45 (0.80) [52] 46 (0.88) [48] 0.90 (0.60–1.36)
aIncludes one pancreatic carcinoma from study 3005 that was erroneously reported as a non-serious adverse event
bThe sum of each location of malignancies differs slightly from the total number owing to the fact that individuals could have malignancies in
more than one location or more than one preferred term may be associated with a malignancy
2504 Diabetologia (2009) 52:2499–2506cancers between patients treated with insulin glargine and
patients treated with NPH insulin.
Nevertheless, this analysis must be considered in light of
some limitations. The duration of most of the studies was
relatively short (mostly 6 months) and does not reflect the
lifetime risk for cancer, while only one study was longer
than 1 year. Nevertheless, if growth promotion is postulated
as the mechanism of any increased cancer risk, it would
appear early in the use of any therapeutic entity. None of
the RCTs was specifically designed to evaluate the risk of
cancer with insulin glargine, although all had mandatory
reporting of adverse events, including treatment-emergent
neoplasms. Randomised controlled trials may not fully
reflect real-life clinical practice; investigators may, for
example, be less likely to include people with previous
malignancies. People using thiazolidinediones, which have
been suggested as protective against breast or pancreatic
cancer [13, 14] and linked with increases in bladder cancer,
[13] were often not included in the insulin studies, owing to
the relative or absolute labelling restrictions in participating
countries. Finally, the number of malignancies reported
here may differ slightly from the published numbers for
each study owing to differences in reporting methods; for
example, only cases classified as serious treatment-
emergent events were included in this analysis, whereas
the original publications may have included cases classified
as non-serious or serious. In addition, we only included
treatment-emergent cases, whereas some of the publications
may have included pre-existing cases.
However, analysis of the 26 uncontrolled trials with
insulin glargine shows that the overall cancer rate is
estimated to be 5.0 cases per 1,000 person-years. Compared
with the age-adjusted incidence rate of 4.63 per 1,000 per
year in the USA (based on cases diagnosed in 2002–2006
from 17 geographic areas included in the Surveillance,
Epidemiology and End Results [SEER] programme), there
was no indication of increased cancer risk in people with
diabetes using insulin glargine. However, we acknowledge
that under-reporting of cancer events can occur in uncon-
trolled observational studies, where follow-up with physi-
cians is not always possible and, therefore, these results
should be interpreted with caution.
For breast cancer, the incidence rate in women partici-
pating in non-interventional trials of insulin glargine may
be estimated to be 82 cases per 100,000 person-years.
Compared with the incidence rate of 124 per 100,000
women per year in the US SEER database, no safety signal
for breast cancer was identified with the use of insulin
glargine in these clinical trials.
In conclusion, these data suggest that insulin glargine is
not associated with an increased risk of cancer compared
with the different comparators (mainly NPH insulin). While
the data provide useful reassuring and contributory infor-
mation regarding the safety of insulin glargine, they
underscore the importance of continued long-term follow
up of participants in clinical trials.
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